The JSW employees have contributed significantly to the success of the Lublin-based biotechnology company. This is an effect of the joint campaigns organized together with the Regional Blood Donation and Treatment Center in Racibórz when blood and plasma were donated by a record number of people.

- Without the plasma collected from recovered patients, the medicine would not have been created. The generosity of donors made its production possible. The attitude adopted by miners is extremely uplifting. By donating their plasma, not only do they save human lives and health, but they also contribute to the endeavors to ensure Poland’s independence from the supply of medicines from abroad. This patriotic attitude deserves great respect – adds Piotr Fic, Management Board Member for Operations at Biomed Lublin SA.

The production process of the first batch of immunoglobulin will take about one and a half months. In early September, the number of antibodies present in the plasma and also the number of vials of medicine that can be produced will be known. The product should be ready for clinical trials at the end of October. This means that the first patient will receive the first dose in about 8-9 weeks. The first conclusions from clinical trials will be available after 4 more months. Sales of the medicine will begin following the registration process.